Capital Management Associates (New York)’s Gilead Sciences GILD Stock Holding History

Capital Management Associates (New York)’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,600	Closed	-$624K	–	83
2019 Q4	$624K	Buy	+9,600	New	+$625K	0.86%	45
2016 Q1	–	Sell	-2,280	Closed	-$231K	–	117
2015 Q4	$231K	Buy	2,280 +100	+5%	+$10.4K	0.34%	123
2015 Q3	$214K	Buy	2,180 +200	+10%	+$22.2K	0.33%	126
2015 Q2	$232K	Buy	+1,980	New	+$216K	0.31%	137

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Management Associates (New York)'s GILD Position: Q1 2020 in Review

Capital Management Associates (New York) sold out of Gilead Sciences (GILD) in Q1 2020, closing a stake of 9,600 shares — an estimated $624K sold.

Capital Management Associates (New York) first reported a position in GILD in Q2 2015 and held it in 4 quarters. The position peaked at $624K in Q4 2019. 1,644 funds tracked by Wall St. Rank hold GILD as of Q1 2020.

Capital Management Associates (New York) reported no remaining Gilead Sciences position as of Q1 2020 after selling out during the quarter.
Capital Management Associates (New York) sold 9,600 Gilead Sciences shares in Q1 2020, an estimated $624K.
Capital Management Associates (New York) first reported a position in Gilead Sciences in Q2 2015 and held it in 4 quarters.
Capital Management Associates (New York)'s Gilead Sciences position peaked at $624K in Q4 2019.
1,644 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2020.

Based on Capital Management Associates (New York)'s 13F filing for Q1 2020, filed 7 May 2020.